You are currently logged into
Hep Directory - My Account or Log Out
Hep Hep
  • Home
  • Basics
    • Basics
    • Introduction
    • Hepatitis A Virus
    • Hepatitis B Virus
    • Hepatitis C Virus
    • NAFLD/NASH
    • Alcoholic Liver Disease
    • Autoimmune Hepatitis
    • Primary Biliary Cholangitis
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Conferences
    • Hep Stories
    • Hep Slideshows
    • Hep TV
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • Opioids
    • Hep A Outbreak Map
    • Newly Diagnosed
    • Help Paying for Treatment
    • Hepatitis C Testing
    • Hepatitis C Medications
    • Hepatitis B Testing
    • Hepatitis B Treatment
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • Bulk Subscriptions
    • Email Newsletter
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • Hep Stories
    • Hep Forums
    • Polls
    • Surveys
    • Ask Hep
    • Services Directory
    • Calendar
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#Phase III

Tweet
  • Share

Gilead Prepares to Submit Sovaldi/Ledipasvir Combo to FDA

A single pill of Sovaldi (sofosbuvir) and ledipasvir, with or without ribavirin, cured 96 percent of people with genotype 1 of HCV in...

Gilead’s Hep C Combo Therapy Shows 100% Cure Rate in Small Study

Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.

Hep C Inhibitor PSI-7977 Goes Interferon-Free in Phase III Studies

Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage...

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.